CD274 and neoplasm: Certain tissue-based biomarkers, such as programmed cell death-ligand 1(PD-L1), defective mismatch repair (MMR) and tumor mutational burden (TMB), have seen widespread use in screening populations that may benefit from ICI therapies (8–10).